BIOMARKER RESULTS FROM PENELOPE, A RANDOMISED PHASE III TRIAL EVALUATING CHEMOTHERAPY plus /- PERTUZUMAB FOR PLATINUM-RESISTANT OVARIAN CANCER (PROC) WITH LOW TUMOUR HER3 MRNA EXPRESSION

被引：0
|
作者：
Colombo, N. [1 ,2 ]
Gonzalez-Martin, A. [3 ,4 ]
Oestergaard, M. Z. [5 ]
Rau, J. [6 ]
Canzler, U. [7 ,8 ]
Fabbro, M. [9 ,10 ]
Martinez, J. [11 ,12 ]
Kiermaier, A. [5 ]
Mitchell, L. [13 ]
Kurzeder, C. [14 ,15 ]
机构：
[1] Univ Milano Bicocca, Div Med Gynecol Oncol, MaNGO, Milan, Italy
[2] Univ Milano Bicocca, European Inst Oncol, Milan, Italy
[3] GEICO, Dept Med Oncol, Madrid, Spain
[4] MD Anderson Canc Ctr Spain, Madrid, Spain
[5] F Hoffmann La Roche, Oncol Biomarker Dev, Basel, Switzerland
[6] Univ Marburg, Coordinating Ctr Clin Trials, Marburg, Germany
[7] AGO, Dept Gynecol & Obstet, Dresden, Germany
[8] Univ Hosp Carl Gustav Carus, Dresden, Germany
[9] GINECO, Dept Med Oncol, Montpellier, France
[10] Ctr Lutte Canc Val dAurelle, Montpellier, France
[11] GEICO, Dept Med Oncol, El Palmar, Spain
[12] Hosp Virgen Arrixaca, El Palmar, Spain
[13] F Hoffmann La Roche, Global Med Affairs Biometr, Basel, Switzerland
[14] AGO, Dept Med Oncol, Essen, Germany
[15] Kliniken Essen Mitte, Essen, Germany
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2015年 / 25卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ESGO-1093
引用
收藏
页码：415 / 417
页数：3
相关论文
共 43 条
  • [1] Biomarker results from PENELOPE, A randomised phase III trial evaluating chemotherapy (CT) ± pertuzumab (P) for platinum-resistant ovarian cancer (PROC) with low tumor HER3 mRNA expression
    Marme, F.
    Grischke, E-M
    Gropp-Meier, M.
    Rau, J.
    Schmalfeldt, B.
    Meier, W.
    Hasenburg, A.
    Belau, A.
    Vergote, I.
    Zorr, A.
    Hils, R.
    Gerber, B.
    du Bois, A.
    Mahner, S.
    Hilpert, F.
    Canzler, U.
    Lueck, H. -J
    Kurzeder, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 94 - 94
  • [2] FINAL OVERALL SURVIVAL RESULTS FROM the DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMISED PHASE III PENELOPE TRIAL EVALUATING PERTUZUMAB IN PLATINUM-RESISTANT OVARIAN CANCER WITH LOW TUMOUR HER3 mRNA EXPRESSION
    Lorusso, D.
    Gonzalez-Martin, A.
    Lueck, H. J.
    Rau, J.
    Selle, F.
    Colombo, N.
    Ottevanger, P.
    Mirza, M. R.
    Berger, R.
    Garcia-Donas, J.
    Grischke, E. M.
    Berton-Rigaud, D.
    Redondo, A.
    Vergote, I.
    Poveda, A.
    Bastiere-Truchot, L.
    Cardona, A.
    du Bois, A.
    Kurzeder, C.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 11 - 12
  • [3] Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer Safety Run-in Results of the PENELOPE Trial
    Gonzalez-Martin, Antonio
    Pautier, Patricia
    Mahner, Sven
    Rau, Joern
    Colombo, Nicoletta
    Ottevanger, Petronella
    del Campo, Josep M.
    Selle, Frederic
    du Bois, Andreas
    Gadducci, Angiolo
    Garcia, Yolanda
    Berton-Rigaud, Dominique
    Marme, Frederik
    Ortega, Eugenia
    Martin, Nicolas
    Bastiere-Truchot, Lydie
    Kiermaier, Astrid
    Kurzeder, Christian
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 (05) : 898 - 905
  • [4] Pertuzumab (P) plus chemotherapy (CT) for platinum-resistant ovarian cancer: Safety run-in results of the PENELOPE trial.
    Gonzalez-Martin, Antonio
    Pautier, Patricia
    Mahner, Sven
    Rau, Joern
    Colombo, Nicoletta
    Ottevanger, Petronella
    Del Campo, Jose Maria
    Berton-Rigaud, Dominique
    Du Bois, Andreas
    Freudensprung, Ulrich
    Walker, Ru-Amir
    Kurzeder, Christian
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer
    Lorusso, Domenica
    Hilpert, Felix
    Gonzalez Martin, Antonio
    Rau, Joern
    Ottevanger, Petronella
    Greimel, Elfriede
    Lueck, Hans-Joachim
    Selle, Frederic
    Colombo, Nicoletta
    Kroep, Judith R.
    Mirza, Mansoor R.
    Berger, Regina
    Pardo, Beatriz
    Grischke, Eva-Maria
    Berton-Rigaud, Dominique
    Martinez-Garcia, Jeronimo
    Vergote, Ignace
    Redondo, Andres
    Cardona, Andres
    Bastiere-Truchot, Lydie
    du Bois, Andreas
    Kurzeder, Christian
    del Campo, J. M.
    Bover, I.
    Barretina-Ginesta, P.
    Ortega, E.
    Garcia, Y.
    Romero, I.
    Poveda, A.
    Herrero, A.
    Vidal, L.
    Rubio, M. J.
    Romeo, M.
    Mendiola, C.
    Arranz, J. A.
    Santaballa, A.
    Gomez de Liano, A.
    Marme, F.
    Mahner, S.
    Canzler, U.
    Zorr, A.
    Gropp-Meier, M.
    Cayir, P.
    Schmalfeldt, B.
    Rautenberg, B.
    Meier, W.
    Belau, A.
    Gerber, B.
    Rein, D.
    Jackisch, C.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 (07) : 1141 - 1147
  • [6] SUBGROUP ANALYSIS BY CHEMOTHERAPY COHORT IN THE AGO-OVAR 2.20/ENGOT-OV14/PENELOPE DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMISED PHASE III TRIAL EVALUATING CHEMOTHERAPY ± PERTUZUMAB FOR PLATINUM-RESISTANT OVARIAN CANCER (PROC)
    Pautier, P.
    Pardo, B.
    Hilpert, F.
    Rau, J.
    Gadducci, A.
    Savarese, A.
    Ottevanger, P.
    Kristensen, G.
    Berger, R.
    Bastiere-Truchot, L.
    Mitchell, L.
    Kurzeder, C.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 24 - 26
  • [7] Patient-reported outcome (PRO) results from the AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomised phase III trial evaluating chemotherapy ± pertuzumab for platinum-resistant ovarian cancer (PROC)
    Hilbert, F.
    Gropp-Meier, M.
    Schmalfeldt, B.
    Rau, J.
    Meier, W.
    Hasenburg, A.
    Belau, A.
    Vergote, I.
    Zorr, A.
    Hils, R.
    Gerber, B.
    du Bois, A.
    Marme, F.
    Mahner, S.
    Canzler, U.
    Lueck, H. -J.
    Grischke, E. -M
    Kurzeder, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 138 - 138
  • [8] PATIENT-REPORTED OUTCOME (PRO) RESULTS FROM THE AGO-OVAR 2.20/ENGOT-OV14/PENELOPE DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMISED PHASE III TRIAL EVALUATING CHEMOTHERAPY ± PERTUZUMAB FOR PLATINUM-RESISTANT OVARIAN CANCER (PROC)
    Hilpert, F.
    Greimel, E.
    Ottevanger, P.
    Rau, J.
    Lorusso, D.
    Kroep, J.
    Mirza, M. Raza
    Zeimet, A.
    Mitchell, L.
    Kurzeder, C.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 465 - 466
  • [9] Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)
    Kristina Lindemann
    Emma Gibbs
    Elisabeth Åvall-Lundqvist
    Rene dePont Christensen
    Kathrine Woie
    Marten Kalling
    Annika Auranen
    Seija Grenman
    Thomas Hoegberg
    Per Rosenberg
    Tone Skeie-Jensen
    Elisabet Hjerpe
    Anne Dørum
    Val Gebski
    Gunnar Kristensen
    British Journal of Cancer, 2017, 116 : 455 - 463
  • [10] Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)
    Lindemann, Kristina
    Gibbs, Emma
    Avall-Lundqvist, Elisabeth
    Christensen, Rene dePont
    Woie, Kathrine
    Kalling, Marten
    Auranen, Annika
    Grenman, Seija
    Hoegberg, Thomas
    Rosenberg, Per
    Skeie-Jensen, Tone
    Hjerpe, Elisabet
    Dorum, Anne
    Gebski, Val
    Kristensen, Gunnar
    BRITISH JOURNAL OF CANCER, 2017, 116 (04) : 455 - 463
12345